Clinical trial NCT00077428: Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
Official title: Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Salivary Gland Cancer
Salivary Gland Adenoid Cystic Carcinoma
Stage III Adenoid Cystic Carcinoma of the Oral Cavity
Stage III Salivary Gland Cancer
Stage IV Adenoid Cystic Carcinoma of the Oral Cavity
Stage IV Salivary Gland Cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
Collaborators: name: SWOG Cancer Research Network
First posted: 2004-02-12
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial is studying how well bortezomib followed by doxorubicin at the time of disease progression works in treating patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (cancer) of the head and neck. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with doxorubicin may kill more tumor cells

Detailed description: OBJECTIVES: Primary I. Determine the objective tumor response in patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma of the head and neck treated with bortezomib.

Secondary I. Determine the time to progression in patients treated with this drug. II. Determine the overall survival of patients treated with this drug. III. Determine the toxic effects of this drug in these patients. IV. Determine the objective tumor response, time to progression, and overall survival of patients who progress on single-agent bortezomib and are then treated with doxorubicin and bortezomib.

V. Determine the toxic effects of this regimen in these patients. VI. Determine the profile and concentration of inflammatory and angiogenic cytokines in serum of patients before and in response to this regimen.

VII. Correlate the expression of biomarkers which may be affected by the ubiquitin-proteasome degradation pathway (NF-kB, p53, p27, cyclin D1, cyclin E, vascular endothelial growth factor \[VEGF\], MVD, V-CAM, and N-CAM) on tumor tissue with the clinical activity of bortezomib in these patients.

OUTLINE: This is a multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 8 years.

PROJECTED ACCRUAL: A total of 23-37 patients will be accrued for this study within 2.3 years.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed adenoid cystic carcinoma of the head and neck

  * Locally advanced, recurrent, or metastatic disease that is considered incurable by known therapies
* Unidimensionally measurable disease
* Must not have stable disease for at least 9 months before study entry
* No known brain metastases
* Performance status - ECOG 0-2
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* AST and ALT no greater than 2.5 times upper limit of normal
* Bilirubin normal
* Creatinine normal
* Creatinine clearance at least 60 mL/min
* LVEF at least lower limit of normal by MUGA
* No history of congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No active or ongoing infection
* No prior allergy to compounds of similar chemical or biological composition to bortezomib
* No other concurrent uncontrolled illness
* No psychiatric illness or social situation that would preclude study compliance
* No pre-existing neuropathy \> grade 1
* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
* See Chemotherapy
* No prior anthracyclines, including any of the following:

  * Doxorubicin
  * Epirubicin
  * Daunorubicin
  * Idarubicin
* No prior mitoxantrone
* No prior high-dose chemotherapy for bone marrow transplantation
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
* At least 3 weeks since prior radiotherapy
* At least 3 weeks since prior surgery
* More than 4 weeks since prior investigational drugs
* No other concurrent anticancer therapy or agents

Primary outcomes:
measure: Objective tumor response (complete and partial overall response) as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
timeFrame: Up to 10 years
Secondary outcomes:
measure: Toxicities, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
timeFrame: Up to 30 days after last dose of study treatment
measure: Progression free survival
timeFrame: Time from randomization or registration to the earlier of disease recurrence or death from any cause, assessed up to 10 years
measure: Overall survival
timeFrame: Time from randomization or registration to date of death (from any cause) or date of last contact, assessed up to 10 years
measure: Association of change in cytokine concentration with response to bortezomib therapy
timeFrame: Up to 1 hour post-treatment (course 2)
measure: Correlation of the expression of biomarkers which may be affected by the ubiquitin-proteasome degradation pathway on tumor tissue with clinical activity
timeFrame: Baseline
Other outcomes:
Locations:
city: Boston
country: United States
facility: Eastern Cooperative Oncology Group
state: Massachusetts
Study officials:
affiliation: Eastern Cooperative Oncology Group
name: Athanassios Argiris
role: PRINCIPAL_INVESTIGATOR
References: